Placenta-derived mesenchymal stromal-like cell therapy (PLX cell therapy) (PLX cell therapy)

Placenta-derived mesenchymal stromal-like cell therapy is an allogeneic cell-based therapeutic modality derived from human placental tissue, specifically designed to promote tissue repair and immunomodulation (PMID: 23911443). These cells, often referred to as PLX (PLacental eXpanded) cells, do not act on a single molecular target but instead function through a paracrine mechanism by secreting a diverse array of cytokines, chemokines, and growth factors in response to environmental cues such as ischemia or inflammation (PMID: 27033215). This multi-targeted approach facilitates angiogenesis, reduces inflammation, and supports the regeneration of damaged muscle and vascular tissues (PMID: 31216724). Clinical applications have focused on conditions like peripheral artery disease, critical limb ischemia, and orthopedic injuries, where the cells help restore blood flow and functional recovery (PMID: 31216724). As an allogeneic therapy, these cells are typically considered immune-privileged, allowing for administration without the need for HLA matching between donor and recipient (PMID: 23911443). The therapeutic effect is transient as the cells are eventually cleared by the host immune system, but the biological signaling they initiate provides lasting clinical benefits. This therapy represents a complex biological product rather than a discrete molecular target, utilizing the cell's natural ability to sense and respond to pathological environments (PMID: 27033215).

Other names

PLX cellsPlacental mesenchymal stem cellsPMSCsPlacenta-derived adherent stromal cellsPLX-PADPLX-R18

The cells act via a paracrine mechanism, secreting various growth factors (e.g., VEGF, Ang-1) and cytokines (e.g., IL-6, IL-10) to promote angiogenesis and immunomodulation (PMID: 27033215, PMID: 31216724).